Novo Holdings A/S is the holding and investment company of the Novo Nordisk Foundation, managing its assets and serving as a leading international life sciences investor. Through its Seeds, Venture, Principal, and Planetary Health Investments teams, it invests in life science companies at all stages of development.
43% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (6 deals in the last 12 months vs 16 prior). Average disclosed round size is $102.9M (across 97 rounds with reported amounts).
Portfolio
104
Fund Size
—
Top Stage
Series A
Last 12 Mo
4
Team
Amit Kakar
Managing Partner Novo Holdings Asia, Life Science Leadership Team
Anders Bendsen Spohr
Managing Partner, Head of Planetary Health Investments Planetary Health Investments
Christoffer Søderberg
Managing Partner Principal Investments, Executive Leadership Team, Life Science Leadership Team
Morten Beck Jørgensen
Managing Partner Capital Investments, Executive Leadership Team, Capital Investments Leadership Team
Scott A. Beardsley
Managing Partner Venture Investments, Novo Holdings US Inc., Life Science Leadership Team
Søren Møller
Managing Partner Seed Investments, Life Science Leadership Team
Aaron Nelson
Partner Venture Investments, Novo Holdings US Inc.
Abhijeet Lele
Senior Partner Principal Investments, Novo Holdings US Inc.
Aleks Engel
Partner Planetary Health Investments, Novo Holdings US Inc.
Amer Sheikh
Partner Seed Investments
Andreas Nickelsen
Partner Capital Investments
Anna Fan
Senior Partner, Public Equity Venture Investments, Novo Holdings US Inc., Life Science Leadership Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Route 92 Medical | Growth | $50M | Apr 2026 |
 Chromologics | Unknown | — | Nov 2025 |
 MATR Foods | Series A | — | Oct 2025 |
 Crystalys | Series A | $205M | Sep 2025 |
| BBridgeBio Oncology Therapeutics | Unknown | $261M | Aug 2025 |
 Avalyn Pharma, Inc. | Series D | $100M | Jul 2025 |
 GlycoEra | Series B | $130M | May 2025 |
 AgNext | Unknown | — | Apr 2025 |
 Augustine Therapeutics | Series A | — | Mar 2025 |
 Callio Therapeutics | Series A | $187M | Mar 2025 |
 Windward Bio | Series A | $200M | Jan 2025 |
 Numab | Series C | $55M | Jan 2025 |
 AnaCardio | Series A | $19M | Jan 2025 |
| BBridgeBio Oncology Therapeutics | Unknown | $260M | Jan 2025 |
 Newleos | Series A | $93M | Jan 2025 |
| CCoave Therapeutics | Series A | $32M | Jan 2025 |
 SiteOne Therapeutics | Series C | $100M | Dec 2024 |
 Nuvig Therapeutics | Series B | $161M | Dec 2024 |
 Antag Therapeutics | Series A | — | Dec 2024 |
 Adcendo | Series B | $135M | Nov 2024 |
 Quanta Dialysis Technologies | Series E | $60M | Nov 2024 |
 Elektrofi, Inc. | Series C | $112.3M | Oct 2024 |
 Booster Therapeutics | Seed | $15M | Oct 2024 |
| QQure.ai | Series D | $65M | Sep 2024 |
| Route 92 Medical | Series F | $50M | Sep 2024 |
Top Co-Investors
Last updated: 9 September 2026